Tag: biotech
-
Medicare to limit coverage of controversial Alzheimer’s drug to clinical trial participants
Prior to CMS’s announcement, the possibility of Medicare covering Aduhelm had already driven increased Medicare Part B premiums.
-
Potential Alzheimer’s treatment approved by FDA
Biogen’s aducanamab could hit the market in a matter of days. While many in the Alzheimer’s community are encouraged by this news, the controversy surrounding the drug hasn’t gone anywhere.
-
Biogen’s Alzheimer’s drug to receive further review
In late January, Biogen announced that the Food and Drug Administration moved the Prescription Drug User Fee Act (PDUFA) action date for its […]
-
What’s next for embattled Alzheimer’s drug aducanamab?
At a J.P. Morgan Healthcare panel on January 11, representatives for Biogen cited Eli Lilly’s positive Phase 2 study of Alzheimer’s drug donanemab […]
-
Positive Phase 2 results for Alzheimer’s drug donanemab
On January 10, pharmaceutical giant Eli Lilly announced positive results in a Phase 2 trial of donanemab, a monoclonal antibody targeting the amyloid-β […]
